Pfizer Company Insiders
PFE Stock | USD 26.26 0.26 1.00% |
About 53% of Pfizer's corporate insiders are selling. The analysis of insiders' sentiment of trading Pfizer Inc stock suggests that many insiders are impartial at this time. Pfizer employs about 88 K people. The company is managed by 54 executives with a total tenure of roughly 367 years, averaging almost 6.0 years of service per executive, having 1629.63 employees per reported executive.
Ian Read Chairman Chairman, CEO and Chairman of Executive Committee |
Douglas Lankler President Executive Vice President General Counsel |
Pfizer's Insider Buying Vs Selling
47
Selling | Buying |
Latest Trades
2024-02-27 | Tommy Tuberville | Acquired @ 26.89 | |||
2024-02-12 | Earl Blumenauer | Acquired @ 27.67 | |||
2023-12-28 | Jared Moskowitz | Disposed @ 28.79 | |||
2023-12-20 | John Boozman | Acquired @ 27.63 | |||
2023-12-18 | Shelley Moore Capito | Disposed @ 27.05 | |||
2023-12-15 | Scott Gottlieb | Acquired 3000 @ 26.47 | View | ||
2023-12-14 | Jerry Moran | Disposed @ 26.14 | |||
2023-12-12 | Kathy E. Manning | Disposed @ 28.58 | |||
2023-12-11 | Sheldon Whitehouse | Disposed @ 28.64 | |||
2023-10-24 | Greg Stanton | Disposed @ 30.43 | |||
2023-09-26 | Greg Stanton | Acquired @ 32.37 | |||
2023-09-11 | C. Scott Franklin | Disposed @ 33.94 | |||
2023-09-08 | Lois Frankel | Disposed @ 34.25 | |||
2023-07-25 | Tommy Tuberville | Acquired @ 37.06 | |||
2023-07-12 | Daniel S. Goldman | Disposed @ 35.99 | |||
2023-06-28 | Lois Frankel | Acquired @ 36.29 | |||
2023-06-12 | Tommy Tuberville | Acquired @ 39.89 | |||
2023-05-26 | Zoe Lofgren | Disposed @ 37.6 | |||
2023-05-08 | Scott Gottlieb | Acquired 1000 @ 38.58 | View |
Monitoring Pfizer's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Pfizer's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Pfizer Inc. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Pfizer's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Pfizer |
Pfizer's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pfizer's future performance. Based on our forecasts, it is anticipated that Pfizer will maintain a workforce of about 90000 employees by May 2024.Pfizer's latest congressional trading
Congressional trading in companies like Pfizer Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Pfizer by those in governmental positions are based on the same information available to the general public.
2024-02-27 | Senator Thomas H Tuberville | Acquired Under $15K | Verify | ||
2024-02-12 | Representative Earl Blumenauer | Acquired Under $15K | Verify | ||
2023-12-20 | Senator John Boozman | Acquired Under $15K | Verify | ||
2023-12-18 | Senator Shelley M Capito | Acquired Under $15K | Verify | ||
2023-12-11 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
2023-10-24 | Representative Greg Stanton | Disposed Under $15K | Verify | ||
2023-09-11 | Representative C. Scott Franklin | Disposed $15K to $50K | Verify | ||
2023-03-03 | Representative Carol Devine Miller | Acquired Under $15K | Verify | ||
2023-01-11 | Representative Michael Patrick Guest | Disposed Under $15K | Verify | ||
2021-12-21 | Senator Jerry Moran | Acquired Under $15K | Verify | ||
2021-08-16 | Representative Mo Brooks | Disposed $15K to $50K | Verify | ||
2021-07-14 | Representative Richard W. Allen | Acquired $15K to $50K | Verify | ||
2021-02-16 | Representative Peter Meijer | Disposed $15K to $50K | Verify | ||
2020-07-09 | Senator Thomas R. Carper | Acquired Under $15K | Verify | ||
2020-07-01 | Representative K. Michael Conaway | Acquired $15K to $50K | Verify | ||
2020-04-07 | Senator Kelly Loeffler | Acquired $100K to $250K | Verify | ||
2020-02-28 | Senator David A Perdue , Jr | Acquired Under $15K | Verify | ||
2019-02-05 | Representative Donna Shalala | Disposed Under $15K | Verify | ||
2018-06-04 | Senator Susan M. Collins | Acquired Under $15K | Verify | ||
2017-09-05 | Senator Shelley Moore Capito | Acquired Under $15K | Verify |
Pfizer Management Team Effectiveness
The company has Return on Asset of 0.0155 % which means that on every $100 spent on assets, it made $0.0155 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0235 %, implying that it generated $0.0235 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of April 23, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B.The current year's Common Stock Shares Outstanding is expected to grow to about 5.7 B. The current year's Net Income Applicable To Common Shares is expected to grow to about 37.9 B
Pfizer Workforce Comparison
Pfizer Inc is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 95,320. Pfizer totals roughly 88,000 in number of employees claiming about 92% of equities under Health Care industry.
Pfizer Profit Margins
The company has Net Profit Margin of 0.04 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of (0.5) %, which entails that for every $100 of revenue, it lost $0.5.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.62 | 0.5006 |
|
| |||||
Net Profit Margin | 0.0344 | 0.0362 |
|
| |||||
Operating Profit Margin | 0.0688 | 0.0724 |
|
| |||||
Pretax Profit Margin | 0.0172 | 0.0181 |
|
| |||||
Return On Assets | 0.0089 | 0.0094 |
|
| |||||
Return On Equity | 0.0226 | 0.0238 |
|
|
Pfizer Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pfizer insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pfizer's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pfizer insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 1.2045 | 53 | 44 | 4,240,517 | 854,465 |
2023-09-01 | 25.0 | 25 | 1 | 6,026 | 0.00 |
2023-06-01 | 39.0 | 39 | 1 | 100,638 | 16,223 |
2023-03-01 | 1.0 | 57 | 57 | 2,792,894 | 1,048,653 |
2022-12-01 | 10.3333 | 31 | 3 | 407,055 | 368,604 |
2022-06-01 | 7.125 | 57 | 8 | 373,722 | 117,822 |
2022-03-01 | 0.9143 | 64 | 70 | 3,135,600 | 1,833,982 |
2021-12-01 | 0.6324 | 43 | 68 | 419,133 | 1,264,052 |
2021-09-01 | 8.5 | 34 | 4 | 48,193 | 4,161 |
2021-06-01 | 14.6667 | 44 | 3 | 65,772 | 16,080 |
2021-03-01 | 0.8933 | 67 | 75 | 4,637,604 | 2,656,850 |
2020-12-01 | 8.75 | 35 | 4 | 23,582 | 187,438 |
2020-06-01 | 2.8421 | 54 | 19 | 78,317 | 208,381 |
2020-03-01 | 0.9663 | 86 | 89 | 5,142,206 | 2,546,317 |
2019-12-01 | 7.0 | 35 | 5 | 6,301 | 12,048 |
2019-09-01 | 2.05 | 41 | 20 | 135,265 | 153,184 |
2019-06-01 | 1.6154 | 42 | 26 | 52,465 | 49,495 |
2019-03-01 | 0.3782 | 104 | 275 | 6,153,830 | 4,978,791 |
2018-12-01 | 8.6 | 43 | 5 | 1,105,760 | 2,247,006 |
2018-09-01 | 0.5625 | 36 | 64 | 204,666 | 1,150,678 |
2018-06-01 | 2.6429 | 37 | 14 | 63,402 | 185,435 |
2018-03-01 | 0.466 | 48 | 103 | 2,406,461 | 2,174,116 |
2017-12-01 | 2.5 | 10 | 4 | 3,234 | 29,450 |
2017-09-01 | 1.1111 | 10 | 9 | 3,282 | 184,543 |
2017-03-01 | 1.0 | 37 | 37 | 1,663,656 | 970,676 |
2016-12-01 | 2.3333 | 21 | 9 | 123,417 | 305,355 |
2016-06-01 | 0.3784 | 28 | 74 | 432,268 | 1,013,128 |
2016-03-01 | 0.9459 | 35 | 37 | 1,637,202 | 994,616 |
2015-12-01 | 17.0 | 17 | 1 | 4,752 | 2,520 |
2015-09-01 | 17.0 | 17 | 1 | 4,759 | 1,000.00 |
2015-06-01 | 3.1111 | 28 | 9 | 105,948 | 104,503 |
2015-03-01 | 0.4536 | 44 | 97 | 1,417,708 | 1,258,003 |
2014-12-01 | 0.9355 | 29 | 31 | 199,816 | 566,489 |
2014-09-01 | 23.0 | 23 | 1 | 8,650 | 1,064 |
2014-06-01 | 5.2 | 26 | 5 | 84,691 | 61,859 |
2014-03-01 | 0.6625 | 53 | 80 | 1,878,990 | 1,541,140 |
2013-12-01 | 2.6471 | 45 | 17 | 144,037 | 243,869 |
2013-09-01 | 5.1 | 51 | 10 | 169,328 | 266,600 |
2013-06-01 | 2.4286 | 51 | 21 | 38,972 | 100,193 |
2013-03-01 | 0.8197 | 50 | 61 | 2,085,489 | 1,401,415 |
2012-12-01 | 5.5 | 33 | 6 | 4,394 | 37,020 |
2012-09-01 | 4.625 | 37 | 8 | 4,692 | 121,517 |
2012-06-01 | 52.0 | 52 | 1 | 53,188 | 19,670 |
2012-03-01 | 3.2143 | 45 | 14 | 2,221,652 | 193,363 |
2011-12-01 | 9.0 | 45 | 5 | 19,412 | 13,403 |
2011-09-01 | 15.0 | 45 | 3 | 10,613 | 35,318 |
2011-06-01 | 25.5 | 51 | 2 | 92,513 | 20,993 |
2011-03-01 | 2.0 | 40 | 20 | 1,616,922 | 99,233 |
2010-12-01 | 1.3929 | 39 | 28 | 8,799 | 811,350 |
2010-09-01 | 18.5 | 37 | 2 | 7,401 | 43,498 |
2010-06-01 | 6.25 | 50 | 8 | 53,762 | 41,614 |
2010-03-01 | 4.6667 | 28 | 6 | 1,827,967 | 203,031 |
2009-12-01 | 10.75 | 43 | 4 | 196,639 | 849.00 |
2009-09-01 | 5.1429 | 36 | 7 | 102,142 | 200,049 |
2009-06-01 | 21.0 | 42 | 2 | 50,384 | 13,600 |
2009-03-01 | 3.2727 | 36 | 11 | 2,303,199 | 505,602 |
2008-09-01 | 50.0 | 50 | 1 | 11,047 | 38,281 |
2008-06-01 | 25.0 | 50 | 2 | 283,066 | 10,000 |
2008-03-01 | 7.6 | 38 | 5 | 1,559,094 | 8,823 |
2007-12-01 | 2.5833 | 31 | 12 | 157,834 | 533,556 |
2007-09-01 | 34.0 | 34 | 1 | 533,595 | 0.00 |
2007-06-01 | 5.125 | 41 | 8 | 161,210 | 104,699 |
2007-03-01 | 2.0667 | 31 | 15 | 1,762,307 | 319,994 |
2006-12-01 | 11.0 | 44 | 4 | 12,115 | 16,146 |
2006-09-01 | 1.56 | 39 | 25 | 858,671 | 1,182,426 |
2006-06-01 | 4.1 | 41 | 10 | 248,777 | 399,464 |
2006-03-01 | 2.9 | 29 | 10 | 2,936,362 | 68,156 |
2005-12-01 | 7.8 | 39 | 5 | 8,765 | 59,925 |
2005-09-01 | 19.5 | 39 | 2 | 357,042 | 655,520 |
2005-06-01 | 6.125 | 49 | 8 | 44,346 | 126,934 |
2005-03-01 | 1.2 | 24 | 20 | 2,336,955 | 1,067,511 |
2004-12-01 | 9.2 | 46 | 5 | 9,714 | 63,616 |
2004-09-01 | 47.0 | 47 | 1 | 26,088 | 17,508 |
2004-06-01 | 21.0 | 63 | 3 | 53,623 | 7,896 |
2004-03-01 | 2.3529 | 40 | 17 | 1,974,456 | 865,954 |
2003-12-01 | 5.2222 | 47 | 9 | 71,159 | 135,061 |
2003-09-01 | 20.5 | 41 | 2 | 25,054 | 19,105 |
Pfizer Notable Stakeholders
A Pfizer stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pfizer often face trade-offs trying to please all of them. Pfizer's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pfizer's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Albert DVM | Chairman CEO | Profile | |
Ian Read | Chairman, CEO and Chairman of Executive Committee | Profile | |
Douglas Lankler | Executive Vice President General Counsel | Profile | |
Mikael Dolsten | Chief Scientific Officer, President - Worldwide Research, Development and Medical | Profile | |
Lidia Fonseca | Executive Vice President, Chief Technology Officer and Digital Officer | Profile | |
Geno Germano | Group President of Global Innovative Pharma Bus. | Profile | |
Laurie Olson | Executive Vice President - Strategy, Portfolio and Commercial Operations | Profile | |
Rady Johnson | Chief Compliance, Quality and Risk Officer, Executive Vice President | Profile | |
Charles Hill | Executive Vice President - Worldwide Human Resources | Profile | |
Albert Bourla | Group President - Vaccines, Oncology and Consumer Healthcare Business | Profile | |
Payal Sahni | Executive Vice President, Chief People Experience Officer | Profile | |
Kirsten LundJurgensen | Executive Vice President and Presidentident - Pfizer Global Supply | Profile | |
Angela Hwang | Group President - Pfizer Biopharmaceuticals Group | Profile | |
Kathrin Jansen | Senior Vice President - Vaccine Research & Development | Profile | |
John Young | Group President - Pfizer Innovative Health and Angela Hwang | Profile | |
Frank DAmelio | Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | Profile | |
Dawn Rogers | Chief Human Resource Officer, Executive Vice President | Profile | |
Alexander Mackenzie | Executive Vice President Chief Development Officer | Profile | |
Sally Susman | Chief Corporate Affairs Officer, Executive Vice President | Profile | |
Anthony Maddaluna | Executive Vice President and Presidentident - Pfizer Global Supply | Profile | |
Freda LewisHall | Executive Vice President Chief Medical Officer | Profile | |
Michael Goettler | Group President - Pfizer Upjohn | Profile | |
Shantanu Narayen | Lead Independent Director | Profile | |
Susan DesmondHellmann | Independent Director | Profile | |
Stephen Sanger | Independent Director | Profile | |
James Quincey | Independent Director | Profile | |
Helen Hobbs | Independent Director | Profile | |
James Smith | Independent Director | Profile | |
Dennis Ausiello | Independent Director | Profile | |
Frances Fergusson | Independent Director | Profile | |
Wyllie Cornwell | Independent Director | Profile | |
Suzanne Johnson | Independent Director | Profile | |
Susan Hockfield | Independent Director | Profile | |
Dan Littman | Independent Director | Profile | |
James Kilts | Independent Director | Profile | |
Don Cornwell | Independent Director | Profile | |
Joseph Echevarria | Independent Director | Profile | |
Scott Gottlieb | Independent Director | Profile | |
Ronald Blaylock | Independent Director | Profile | |
Payal Becher | Chief VP | Profile | |
Jennifer Damico | Senior Vice President Principal Accounting Officer, Controller | Profile | |
Aamir Malik | Executive Vice President Chief Business Innovation Officer | Profile | |
Christopher Stevo | Senior Vice President and Chief Investor Relations Officer | Profile | |
William Carapezzi | Executive Vice President - Global Business Services and Transformation | Profile | |
Mikael MD | Chief Development | Profile | |
Mike Mcdermott | Executive Vice President Chief Global Supply Officer | Profile | |
Christopher CFA | VP Officer | Profile | |
Michael Mcdermott | Executive Vice President Chief Global Supply Officer | Profile | |
Francesca DeMartino | Chief Officer | Profile | |
Gordon Loh | Senior Vice President Corporate Audit | Profile | |
David Denton | Chief VP | Profile | |
DVM DVM | Chairman CEO | Profile | |
William Gray | Independent Director | Profile | |
Andreas Panayiotou | Global Officer | Profile |
About Pfizer Management Performance
The success or failure of an entity such as Pfizer Inc often depends on how effective the management is. Pfizer management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pfizer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pfizer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.02 | 0.02 | |
Return On Capital Employed | 0.02 | 0.02 | |
Return On Assets | 0.01 | 0.01 | |
Return On Equity | 0.02 | 0.02 |
The data published in Pfizer's official financial statements usually reflect Pfizer's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Pfizer Inc. For example, before you start analyzing numbers published by Pfizer accountants, it's critical to develop an understanding of what Pfizer's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Pfizer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pfizer Inc. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.
Pfizer Workforce Analysis
Traditionally, organizations such as Pfizer use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pfizer within its industry.Pfizer Manpower Efficiency
Return on Pfizer Manpower
Revenue Per Employee | 664.7K | |
Revenue Per Executive | 1.1B | |
Net Income Per Employee | 24.2K | |
Net Income Per Executive | 39.5M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.